Here, we report the results of a validation study of the Khorana score and VTE risk, including gene mutations, such as epidermal growth factor receptor (EGFR) gene mutation status and anaplastic lymphoma kinase (ALK) fusion gene, using data from a prospective observational study of advanced lung cancer (the Rising-VTE/NEJ037 study). The gene discussed is ALK; the disease is lung carcinoma.